Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants

key information

study id #: NCT04718181

condition: Muscular Atrophy, Spinal

status: Recruiting


The study is a randomized, single oral dose, crossover study in up to three parts to investigate the relative bioavailability and bioequivalence of two different formulations of risdiplam 5 mg (dispersible tablets) versus the current risdiplam oral solution formulation in healthy male and female participants. The effect of food on these two dispersible tablets and the current oral solution will be studied, as well as the effect of omeprazole on the dispersible tablets.

intervention: risdiplam, omeprazole


last updated: March 03, 2022